Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Crosses Below Fifty Day Moving Average - Should You Sell?

Key Points

• Price action: Elite Pharmaceuticals (OTCMKTS:ELTP) fell below its 50-day moving average of $0.40, trading as low as $0.3606 and last at $0.3753 on a volume of 166,781 shares.
• Valuation and balance-sheet strength: The company has a market cap of $404.24M, a P/E of 12.51 and a low beta (0.46), with very strong liquidity (quick ratio 5.44, current ratio 7.34) and minimal leverage (debt/equity 0.05).
• Recent results: In the latest quarter (reported Feb. 17) Elite posted $0.01 EPS on $31.59M revenue, with a net margin of 30.98% and a return on equity of 47.93%.

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report)'s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.40 and traded as low as $0.3606. Elite Pharmaceuticals shares last traded at $0.3753, with a volume of 166,781 shares trading hands.

Elite Pharmaceuticals Stock Down 1.2%

The firm's 50 day simple moving average is $0.40 and its 200 day simple moving average is $0.50. The company has a market cap of $404.24 million, a price-to-earnings ratio of 12.51 and a beta of 0.46. The company has a quick ratio of 5.44, a current ratio of 7.34 and a debt-to-equity ratio of 0.05.

Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last announced its quarterly earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%. The company had revenue of $31.59 million for the quarter.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.